Golpanian Rachel Shireen, Yosipovitch Gil
Department of Dermatology and Cutaneous Surgery, and Itch Center, University of Miami Miller School of Medicine , Miami, FL, USA.
Expert Opin Pharmacother. 2020 Sep;21(13):1629-1636. doi: 10.1080/14656566.2020.1775815. Epub 2020 Jun 9.
Pruritus is a debilitating symptom that significantly affects the quality of life of patients who suffer from it. Many current and emerging systemic treatments targeting the neural system have been successful in treating itch of various underlying etiologies.
A complete search of the PUBMED and Google Scholar databases was completed and literature pertinent to current and emerging systemic anti-pruritic drugs which target the neural system was compiled. The purpose of this review is to give the reader with an overview of the current and emerging systemic therapeutic options which target the neural system for chronic pruritus. The authors then provide the reader with their expert perspectives on the future of these therapies.
Exciting new anti-pruritic therapies targeting the neural system which show promise include NK-1 inhibitors, opioid receptor modulators, and drugs targeting specific itch receptors such as Mrgpr, Na1.7, and PAR2, as well as selective GABA modulators. Future studies should be conducted in order to fully understand these exciting therapeutic options.
瘙痒是一种使人衰弱的症状,严重影响患者的生活质量。目前许多针对神经系统的新兴全身治疗方法已成功治疗了各种潜在病因引起的瘙痒。
完成了对PUBMED和谷歌学术数据库的全面检索,并汇编了与当前和新兴的针对神经系统的全身抗瘙痒药物相关的文献。本综述的目的是向读者概述当前和新兴的针对慢性瘙痒的神经系统全身治疗选择。作者随后向读者提供了他们对这些疗法未来发展的专业观点。
有前景的令人兴奋的新型针对神经系统的抗瘙痒疗法包括NK-1抑制剂、阿片受体调节剂、针对特定瘙痒受体(如Mrgpr、Na1.7和PAR2)的药物以及选择性GABA调节剂。应开展进一步研究以充分了解这些令人兴奋的治疗选择。